Merck KGaA raised its full-year profit outlook after stronger demand for laboratory and drug-manufacturing supplies helped the German science and technology group start 2026 ahead of market expectations, giving investors a clearer earnings catalyst after a period marked by foreign-exchange pressure, biotech-sector caution and patent concerns in healthcare.

The Darmstadt-based company said on May 13 that it now expects 2026 EBITDA pre, its preferred adjusted operating profit measure, in a range of €5.7 billion to €6.1 billion. That compares with a previous forecast of €5.5 billion to €6.0 billion and reflects what management described as stronger business momentum, particularly in Life Science. The company also lifted its net sales outlook to €20.4 billion to €21.4 billion, compared with an earlier range of €20.0 billion to €21.1 billion.

The update was significant because Merck’s original 2026 guidance had been framed by a difficult mix of headwinds: unfavorable currency translation, the expected U.S. erosion of Mavenclad, and an only gradual recovery in life-science demand after several quarters of inventory normalization across the biotech and pharmaceutical supply chain. The first-quarter numbers did not remove those risks, but they gave investors enough evidence to price in a better earnings floor.

Merck reported first-quarter net sales of about €5.1 billion, down 2.8% on a reported basis from the prior-year period. The decline reflected strong negative exchange-rate effects, even as the company generated organic sales growth of 2.9%. EBITDA pre was €1.53 billion, broadly stable against the year-earlier quarter and above consensus expectations cited by Reuters. The result showed that the group was able to preserve profitability despite reported revenue pressure and a still-uneven demand backdrop.

Life Science was the main earnings story. The unit, which includes laboratory materials, bioprocessing products and supplies used in pharmaceutical manufacturing, recorded stronger underlying growth as Process Solutions accelerated. Merck said the business benefited from demand tied to drug-manufacturing equipment and supplies, while the company also pointed to some safety-stock building related to regional developments. For investors, the unit’s performance suggested that the long downturn in life-science tools may be easing faster than expected, at least in parts of the portfolio most exposed to biopharma production.

Life Science net sales rose 2.2% on a reported basis to €2.27 billion in the quarter, but the underlying picture was stronger: organic growth reached 7.4%, with exchange rates reducing reported growth by 4.8 percentage points. EBITDA pre for the business rose 4.1% to €648 million. Merck said gross profit improved after adjustments, supported by double-digit organic growth in Process Solutions and production-cost optimization, though inflation and currency effects remained offsets.

The distinction between reported and organic performance is important in assessing the quarter. Merck is a euro-reporting multinational with substantial exposure to currencies outside the eurozone. In the first quarter, foreign-exchange movements reduced reported group sales and weighed on adjusted earnings. Without those translation effects, the operating recovery would have looked materially stronger. That is why the guidance raise carried weight: management raised the adjusted profit range despite acknowledging that currency remains a constraint on reported results.

The healthcare business added a second element to the outlook shift. Merck has been preparing investors for lower U.S. sales of Mavenclad, its multiple-sclerosis treatment, after loss of exclusivity and the expected arrival of generic competition. Reuters reported that the expected decline in U.S. Mavenclad sales, previously anticipated to start in March, had been delayed to May. That timing benefit supported the first-quarter result and helped reduce the near-term earnings drag, though it does not eliminate the structural pressure on the product.

Healthcare therefore remains a transitional business for Merck. The group is balancing Mavenclad erosion with existing franchises and new growth assets, including its planned $3.9 billion acquisition of SpringWorks Therapeutics. The SpringWorks transaction is intended to strengthen Merck’s oncology and rare-tumor pipeline, adding commercial and development-stage assets that could become more important as older products mature. In the near term, however, the first-quarter earnings story was less about a healthcare acceleration than about resilience and timing.

Merck’s Electronics business also contributed to the group’s operating picture, though it was not the primary driver of the guidance raise. The unit, which supplies materials used in semiconductor production and display technologies, reported organic sales growth, helped by semiconductor materials demand tied to artificial intelligence and advanced chips. Reported sales, however, were reduced by currency effects and the impact of portfolio changes. The segment remains strategically important because semiconductor materials give Merck exposure to a long-cycle technology investment theme, but the first-quarter market reaction centered more on Life Science.

The share-price response reflected that focus. Merck shares rose sharply after the results, with Reuters reporting an 8% gain and other market reports showing a similar move. The rally suggested that investors had entered the quarter with cautious expectations and were prepared to reward evidence that Life Science demand is recovering and that management’s original 2026 profit outlook may have been conservative. It also gave newly appointed Chief Executive Kai Beckmann a positive opening update after taking over from Belén Garijo.

For Beckmann, the quarter creates both opportunity and a higher bar. Merck’s portfolio is diversified, but each major division faces a distinct earnings test. Life Science must prove that demand recovery is broad and durable rather than driven by temporary ordering patterns. Healthcare must manage the Mavenclad decline while showing that pipeline and acquisition-led growth can replace lost exclusivity. Electronics must convert semiconductor demand into more consistent reported growth despite currency and portfolio effects. The guidance raise indicates that management sees enough strength across the group to lift expectations, but it does not remove execution risk.

The upgraded EBITDA pre range also implies a tighter and more constructive earnings setup for the rest of the year. At the midpoint, the new guidance points to €5.9 billion of adjusted operating profit, compared with €5.75 billion at the midpoint of the prior range. That still leaves Merck below the €6.1 billion reported for 2025, underscoring that 2026 remains a year of pressure rather than a clean expansion year. But it narrows the perceived downside and signals that the company may be navigating the early-year headwinds better than initially projected.

Analysts and investors are likely to focus on three questions over the next several quarters. The first is whether Process Solutions can sustain double-digit growth as customer ordering patterns normalize. The second is whether the timing benefit around Mavenclad merely shifts pressure into later quarters or reduces the full-year earnings hit more meaningfully. The third is whether exchange-rate pressure continues to obscure underlying performance, particularly if the euro remains strong against key operating currencies.

Merck’s full-year sales guidance also deserves attention because the raised range implies that management is not relying solely on margin protection to lift profit expectations. The company now expects stronger top-line support than it did at the start of the year, with organic sales growth projected to be better than previously indicated. That matters for quality of earnings: a guidance raise backed by end-market demand typically carries more credibility than one driven only by cost cuts, timing items or lower spending.

The life-science tools sector has been closely watched because it experienced a sharp demand distortion after the pandemic. During the boom, laboratories, drug manufacturers and biotech customers built capacity and inventory. As demand normalized, suppliers faced destocking, reduced equipment orders and slower customer spending. Merck’s first-quarter update suggests that the recovery may now be appearing in areas tied to drug production and bioprocessing, even if the broader sector remains uneven. The company’s reference to limited safety-stock building also means investors will need to separate recurring demand from precautionary ordering.

From an earnings perspective, the quarter strengthens the case that Merck has entered 2026 with more operating flexibility than its March guidance suggested. The company is still contending with a lower reported sales base, a stronger currency drag and product-specific pressure in healthcare. Yet the combination of better-than-expected adjusted EBITDA, stronger Life Science momentum and an upgraded full-year range changes the market narrative from downside protection to selective recovery.

The comparison with Siemens, another German industrial and technology group that recently reported an earnings miss but maintained its outlook, is also instructive for the broader European earnings season. Investors have been rewarding companies that can show order strength, pricing resilience or guidance stability despite macro uncertainty. Merck’s update went one step further by raising guidance, and that helped differentiate the stock within a market still sensitive to currency effects, China exposure, U.S. demand risk and sector-specific destocking cycles.

The main caution is that Merck’s upgraded forecast still depends on conditions that can shift quickly. Life-science demand can be lumpy, particularly in large bioprocessing orders. Healthcare earnings remain exposed to generic competition and regulatory timelines. Electronics depends partly on semiconductor capital spending and materials demand, both of which can be cyclical even when long-term AI-related demand is strong. Management’s guidance raise is therefore a positive signal, but not a guarantee that all three businesses have moved into synchronized growth.

Still, the first-quarter report gives Merck a stronger earnings base for 2026 than investors had expected at the start of the year. The raised adjusted profit range, the resilience of EBITDA pre and the recovery signs in lab supplies provide the central investment message: Merck is not yet through all of its headwinds, but its most important life-science engine is showing enough improvement to lift the company’s full-year outlook.

For Wall Street Review’s earnings lens, the key takeaway is that Merck’s quarter was a guidance event more than a simple results event. Reported sales declined, and net profit was still under pressure, but the company’s adjusted operating performance exceeded expectations and management raised the annual profit framework. That combination shifted investor attention away from currency and patent risk and toward the possibility that Life Science recovery can provide a more durable earnings bridge through 2026.